6HRT image
Deposition Date 2018-09-28
Release Date 2019-03-20
Last Version Date 2024-05-15
Entry Detail
PDB ID:
6HRT
Keywords:
TRANSFERASE
Title:
CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 12-(6-tert-butyl-8-fluoro-1-oxo-phthalazin-2-yl)-9-hydroxy-6-methyl-4-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6-azatricyclo[9.4.0.02,7]pentadeca-1(15),2(7),3,11,13-pentaen-5-one
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Spodoptera frugiperda
Method Details:
Experimental Method:
X-RAY DIFFRACTION
Resolution:
1.36 Å
R-Value Free:
0.20
R-Value Work:
0.17
R-Value Observed:
0.17
Space Group:
P 21 21 2
6HRT validation report
Macromolecular Entities
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Tyrosine-protein kinase BTK
Gene (Uniprot):BTK
Mutations:M489A, R492A, E624A, K625A
Chain IDs:A
Chain Length:283
Number of Molecules:1
Biological Source:Homo sapiens
UniProt ID:Q06187 Pfam ID:PF07714 EC:2.7.10.2
Ligand Molecules
GMW
Primary Citation
A potent seven-membered cyclic BTK (Bruton's tyrosine Kinase) chiral inhibitor conceived by structure-based drug design to lock its bioactive conformation.
Bioorg.Med.Chem.Lett. 29 1074 1078 (2019)
PMID: 30857747 DOI: 10.1016/j.bmcl.2019.03.001

Abstact

A seven-membered cyclic chiral analog of potent lead BTK inhibitor 1 was envisioned by structure-based design to lock the molecule into its bioactive conformation. For the elaboration of the seven-membered ring, compound 1 pyridone 6-position was substituted with the purpose to prevent formation of reactive metabolites. Eventually, the cyclic chiral compound 3 maintained the high potency of 1, and most importantly showed no activity at either GSH or TDI assays suggesting no formation of reactive metabolites. The anticipated bound conformation of 3 to BTK was confirmed by X-ray crystallography. Synthetically, the crucial seven-membered ring formation was obtained by using TosMIC as a connective reagent.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
6HRP